We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Gastrointestinal Bypass Device Offers an Alternative to Diverting Stoma

By HospiMedica International staff writers
Posted on 20 Jan 2020
A novel temporary intraluminal bypass device reduces diverting stoma rates in patients undergoing gastrointestinal resection procedures.

The Colospan (Kfar Saba, Israel) CG-100 is designed to reduce the rate of diverting stoma and related complications by diverting fecal material from contacting with the anastomotic site during the initial critical healing period. The device itself is comprised of a tubular silicone sheath that is introduced into the lumen of the intestinal tract through the anus, using a designated delivery system. The sheath is positioned proximal of the anastomosis. At the distal part of the sheath there are three inflatable balloons and an extra-luminal ring which encircles the colon.

Image: An intraluminal bypass device reduces diverting stoma complications (Photo courtesy of Colospan)
Image: An intraluminal bypass device reduces diverting stoma complications (Photo courtesy of Colospan)

The diameter of the balloon is slightly larger than that of the ring, preventing the sheath from moving downstream beyond the ring location, while still allowing it to move freely inside the colon, preventing damage to the colon wall. After ten days, when the risk for anastomotic leakage is reduced, the sheath is removed under x-ray guidance without any additional surgical intervention, in a procedure that requires only a few minutes. The CG-100 has received the European Community (EC) mark of approval and has been granted an U.S Food and Drug Administration (FDA) investigational device exemption (IDE).

“Colospan will launch a prospective, randomized pivotal study which is a leap forward towards bringing our novel device closer to the market,” said Boaz Assaf, CEO of Colospan. “The pivotal study will allow us to assess the potential of our device to improve patients' lives, significantly reduce healthcare costs, and as a result empower physicians to deliver an improved standard of care.”

The major concern of colorectal surgeons is anastomotic leakage of colon content into the abdominal cavity, which often necessitates a diverting stoma to prevent anastomotic leakage during the healing period. But diverting stoma is known to cause significant complications during its presence, which can last up to six months, and as a result of the second procedure required for stoma closure. Given the risks associated with stomas, a temporary diversion solution can provide surgeons as an alternative, short solution.

Related Links:
Colospan


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Examination Table
Powerline Backrest Top

Latest Surgical Techniques News

Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices

Custom 3D-Printed Orthopedic Implants Transform Joint Replacement Surgery

Wearable Technology Monitors and Analyzes Surgeons' Posture during Long Surgical Procedures